William E. Alborn

3.4k citations

35 papers · 2.1k indexed · h-index 23

Impact in

Molecular Medicine top 2%
- Antibiotic Resistance in Bacteria
Cancer Research top 5%
- Cancer, Hypoxia, and Metabolism
- Cancer, Lipids, and Metabolism

Papers in ⓘ

Molecular Medicine 2
Molecular Biology 23
- Peroxisome Proliferator-Activated Receptors 5
- Phenothiazines and Benzothiazines Synthesis and Activities 3
- Biochemical and Structural Characterization 3

Co-authors: Norris E. Allen (7 shared papers)Robert J. Konrad (14 shared papers)J N Hobbs (5 shared papers)Guoqing Cao (6 shared papers)David A. Preston (7 shared papers)Jason S. Troutt (4 shared papers)Roslyn Davis (1 shared paper)Michael D. Knierman (3 shared papers)
Journals: Antimicrobial Agents and Chemotherapy (6 papers)Journal of Lipid Research (4 papers)Clinical Chemistry (4 papers)Journal of Bacteriology (3 papers)Journal of Medicinal Chemistry (3 papers)
Partner nations: United States Türkiye

In The Last Decade

William E. Alborn

35 papers receiving 2.1k citations

Peers

Countries citing papers authored by William E. Alborn

Since Specialization

Citations

This map shows the geographic impact of William E. Alborn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William E. Alborn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William E. Alborn more than expected).

Fields of papers citing papers by William E. Alborn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William E. Alborn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William E. Alborn. The network helps show where William E. Alborn may publish in the future.

Co-authors

The 25 scholars most cited alongside William E. Alborn, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with William E. Alborn Line = papers co-authored together William E. Alborn links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 35 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	SLC1A5 Mediates Glutamine Transport Required for Lung Cancer Cell Growth and Survival Clinical Cancer Research ·Mohamed Hassanein, Megan D. Hoeksema, Masakazu Shiota, Jun Qian, Bradford K. Harris, Heidi Chen, Jonathan E. Clark, William E. Alborn, Rosana Eisenberg, Pierre P. Massion	2012	283
2	Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9 Journal of Lipid Research ·Holly E. Careskey, Roslyn Davis, William E. Alborn, Jason S. Troutt, Guoqing Cao, Robert J. Konrad	2007	261
3	Daptomycin disrupts membrane potential in growing Staphylococcus aureus Antimicrobial Agents and Chemotherapy ·William E. Alborn, Norris E. Allen, David A. Preston	1991	175
4	The Novel Apolipoprotein A5 Is Present in Human Serum, Is Associated with VLDL, HDL, and Chylomicrons, and Circulates at Very Low Concentrations Compared with Other Apolipoproteins Clinical Chemistry ·Peter J. O’Brien, William E. Alborn, John H. Sloan, Maverick Ulmer, Amechand Boodhoo, Michael D. Knierman, A. Eric Schultze, Robert J. Konrad	2004	167
5	Serum Proprotein Convertase Subtilisin Kexin Type 9 Is Correlated Directly with Serum LDL Cholesterol Clinical Chemistry ·William E. Alborn, Guoqing Cao, Holly E. Careskey, Yuewei Qian, Danise R Subramaniam, Julian Davies, Elaine M. Conner, Robert J. Konrad	2007	132
6	Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032 Antimicrobial Agents and Chemotherapy ·Norris E. Allen, J N Hobbs, William E. Alborn	1987	129
7	Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo Biochemical and Biophysical Research Communications ·Robert J. Schmidt, Thomas P. Beyer, William R. Bensch, Yuewei Qian, Aiming Lin, Mark C. Kowala, William E. Alborn, Robert J. Konrad, Guoqing Cao	2008	85
8	Inhibition of membrane potential-dependent amino acid transport by daptomycin Antimicrobial Agents and Chemotherapy ·Norris E. Allen, William E. Alborn, J N Hobbs	1991	77
9	Genetic and enzymatic basis of hygromycin B resistance in Escherichia coli Antimicrobial Agents and Chemotherapy ·R.Nagaraja Rao, Norris E. Allen, J N Hobbs, William E. Alborn, Herbert A. Kirst, Jonathan W. Paschal	1983	75
10	Identification and Characterization of a Monofunctional Glycosyltransferase from Staphylococcus aureus Journal of Bacteriology ·Q. May Wang, Robert B. Peery, Robert B. Johnson, William E. Alborn, W K Yeh, Paul L. Skatrud	2001	63
11	Alloxan is an inhibitor of O-GlcNAc-selective N-acetyl-β-d-glucosaminidase Biochemical and Biophysical Research Communications ·Thomas N. Lee, William E. Alborn, Michael D. Knierman, Robert J. Konrad	2006	58
12	Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels Journal of Lipid Research ·Jason S. Troutt, William E. Alborn, Guoqing Cao, Robert J. Konrad	2009	57
13	Comparison of Protein Immunoprecipitation-Multiple Reaction Monitoring with ELISA for Assay of Biomarker Candidates in Plasma Journal of Proteome Research ·De Lin, William E. Alborn, Robbert J.C. Slebos, D.C. Liebler	2013	51
14	A80915, a new antibiotic complex produced by Streptomyces aculeolatus. Discovery, taxonomy, fermentation, isolation, characterization, and antibacterial evaluation. The Journal of Antibiotics ·D. S. Fukuda, Jon S. Mynderse, Patrick J. Baker, D. M. BERRY, L. D. BOECK, R. C. Yao, FREDERICK P. MERTZ, Walter M. Nakatsukasa, J. A. Mabe, J. L. OTT, F. T. COUNTER, P. W. Ensminger, Norris E. Allen, William E. Alborn, J N Hobbs	1990	51
15	7-Hydroxytropolone: an inhibitor of aminoglycoside-2"-O-adenylyltransferase Antimicrobial Agents and Chemotherapy ·Norris E. Allen, William E. Alborn, J N Hobbs, Herbert A. Kirst	1982	46
16	Biochemical characterization of penicillin-resistant and -sensitive penicillin-binding protein 2x transpeptidase activities of Streptococcus pneumoniae and mechanistic implications in bacterial resistance to beta-lactam antibiotics Journal of Bacteriology ·Genshi Zhao, W K Yeh, Robert H. Carnahan, J E Flokowitsch, Timothy I. Meier, William E. Alborn, Gerald W. Becker, S. Richard Jaskunas	1997	45
17	Anti‐Candida Activity and Toxicology of LY121019, a Novel Semisynthetic Polypeptide Antifungal Antibiotica Annals of the New York Academy of Sciences ·Robert S. Gordee, Douglas J. Zeckner, Leonard C. Howard, William E. Alborn, Manuel Debono	1988	44
18	Analytical Validation and Biological Evaluation of a High–Molecular-Weight Adiponectin ELISA Clinical Chemistry ·Madhur K. Sinha, Traci Songer, Qiang Xiao, John H. Sloan, Jin Wang, Shaoquen Ji, William E. Alborn, Randy A Davis, Michael M. Swarbrick, Kimber L. Stanhope, Bruce M. Wolfe, Peter J. Havel, Todd Schraw, Robert J. Konrad, Philipp E. Scherer, Jehangir Mistry	2007	40
19	Administration of a PPARα agonist increases serum apolipoprotein A-V levels and the apolipoprotein A-V/apolipoprotein C-III ratio Journal of Lipid Research ·A. Eric Schultze, William E. Alborn, Ronald K. Newton, Robert J. Konrad	2005	38
20	An apolipoprotein A-I mimetic dose-dependently increases the formation of preβ1 HDL in human plasma Journal of Lipid Research ·Jason S. Troutt, William E. Alborn, Marian Mosior, Jiannong Dai, Anthony Murphy, Thomas P. Beyer, Youyan Zhang, Guoqing Cao, Robert J. Konrad	2007	36

About William E. Alborn

William E. Alborn is a scholar working on Molecular Medicine, Molecular Biology, Organic Chemistry, Endocrinology, Diabetes and Metabolism and Toxicology, having authored 35 papers that have together received 2.1k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (7 papers), Bacterial Genetics and Biotechnology (6 papers), Peroxisome Proliferator-Activated Receptors (5 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (5 papers), Carbohydrate Chemistry and Synthesis (4 papers), Antimicrobial Resistance in Staphylococcus (4 papers), Phenothiazines and Benzothiazines Synthesis and Activities (3 papers) and Biochemical and Structural Characterization (3 papers). The work is most often cited by research in Molecular Medicine (194 citations), Cancer Research (328 citations), Infectious Diseases (365 citations), Microbiology (121 citations) and Biochemistry (139 citations). William E. Alborn has collaborated with scholars based in United States and Türkiye. Frequent co-authors include Norris E. Allen, Robert J. Konrad, J N Hobbs, Guoqing Cao, David A. Preston, Jason S. Troutt, Roslyn Davis, Michael D. Knierman, A. Eric Schultze and Megan D. Hoeksema. Their work appears in journals such as Antimicrobial Agents and Chemotherapy, Journal of Lipid Research, Clinical Chemistry, Journal of Bacteriology and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact